COVID-19 in a patient with hypocomplementemic urticarial syndrome and MPO-ANCA vasculitis on hemodialysis treated with omalizumab

Nefrologia (Engl Ed). 2021 May-Jun;41(3):354-355. doi: 10.1016/j.nefroe.2020.07.003. Epub 2021 Jul 21.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Antineutrophil Cytoplasmic
  • COVID-19* / complications
  • Humans
  • Omalizumab / therapeutic use
  • Renal Dialysis
  • Syndrome
  • Urticaria* / complications
  • Urticaria* / drug therapy
  • Vasculitis*

Substances

  • Antibodies, Antineutrophil Cytoplasmic
  • Omalizumab